<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03975517</url>
  </required_header>
  <id_info>
    <org_study_id>7300</org_study_id>
    <nct_id>NCT03975517</nct_id>
  </id_info>
  <brief_title>Sexual Risks in Prep Users</brief_title>
  <acronym>PREP</acronym>
  <official_title>Analysis of Sexual Risks in Prep (Pre-exposure Prophylaxis) Users Followed-up in a University Care Centre (Le Trait d'Union)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary purpose of the study: to describe sexual behavior of Prep users, whatever mode of&#xD;
      intake, ie continuous or on-demand; it has been shown in some studies, an increase of sexual&#xD;
      risks in Prep users, and therefore an similar increase of STIs (sexually transmitted&#xD;
      diseases); using a self-questionnaire, we'd like to evaluate sexual behavior before, and 6&#xD;
      months after, starting Prep.&#xD;
&#xD;
      Secondary purposes: to describe medical characteristics of Prep users (past medical&#xD;
      condition, demographic characteristics, vaccinations, kidney function, serological results,&#xD;
      urine and anal/pharyngeal swabs), clinical and biological Prep safety, STIs occurrence, and&#xD;
      antibiotic prescriptions, continuous or on-demand intake, Prep indication.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Actual">June 4, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of sexual behavior in Prep users</measure>
    <time_frame>6 months</time_frame>
    <description>Sexual behavior will be evaluated with a questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the medical profile of the Strasbourgeoise active file</measure>
    <time_frame>6 months</time_frame>
    <description>Describe the active line of people using Prep and followed in the center</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>HIV Infection</condition>
  <condition>Prep Prescription</condition>
  <condition>Vaccinations</condition>
  <condition>Sexually Transmitted Diseases</condition>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>PrEP</intervention_name>
    <description>Define the behavioral characteristics of the active file of patients using PrEP in Strasbourg in 2019.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non HIV-infected subjects, who have a high risk to be infected by HIV, mostly because of&#xD;
        non protected sexual intercourse.&#xD;
&#xD;
        Most of them are MSM (men who have sex with men). And who started Prep&#xD;
        (emtricitable/tenofovir disoproxil fumarate), or will initiate Prep&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  non HIV-infected subjects&#xD;
&#xD;
          -  men aged 18 years or older&#xD;
&#xD;
          -  having non protected sexual relationship&#xD;
&#xD;
          -  taking Prep (emtricitable/tenofovir disoproxil fumarate) either every day, or&#xD;
             on-demand&#xD;
&#xD;
          -  affiliated to social security&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  HIV-infected patients&#xD;
&#xD;
          -  refusal of study participation&#xD;
&#xD;
          -  not on Prep&#xD;
&#xD;
          -  not fluent in French language&#xD;
&#xD;
          -  safeguarding justice&#xD;
&#xD;
          -  on guardianship or trusteeship&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David REY</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David REY</last_name>
    <phone>+33 3.69.55.13.51</phone>
    <email>David.rey@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Les Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David REY</last_name>
      <phone>+33 3.69.55.13.51</phone>
      <email>David.rey@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>David REY</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Laure BATARD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christine CHENEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2019</study_first_posted>
  <last_update_submitted>August 19, 2019</last_update_submitted>
  <last_update_submitted_qc>August 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prep</keyword>
  <keyword>Sexual behavior</keyword>
  <keyword>HIV</keyword>
  <keyword>Syphilis</keyword>
  <keyword>Chlamydia infection</keyword>
  <keyword>Hepatitis</keyword>
  <keyword>Gonococcus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sexually Transmitted Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

